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ABSTRACT 
Objective: In this present research, formulation of floating multiple unit minitablets of metoprolol succinate without using gas generating agent 
was attempted with an objective of increased residence time, sustained release, and improved oral bioavailability. 
Methods: Solid dispersions were prepared with lipophilic carriers such as compritol ATO888, Gelucire 43/01, Gelucire 39/01, and precirol ATO 05 
was formulated using fusion technique. Neusillin US2 was used as an adsorbent. The solid dispersions were compressed into minitablets, weighing 
20 mg, and then filled into ‘0’ size capsule. 
Results: Formulation F9, F10, F14, and F15 showed instantaneous floating lag time, i.e., 0 min, floating time more than 12 h, and sustained release up to 
12 h. Pharmacokinetic study of the optimized formulation (F9) showed 2.46 times increase in area under the curve with increased residence time. 
Conclusion: Hence gelucire 43/01 based floating multiple unit minitablets of metoprolol succinate can be considered a promising approach.  
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INTRODUCTION 
For a long time, oral controlled release (CR) formulations are 
popularly used for controlling the release of drugs. Short transit time 
of drug with absorption window in the stomach causes drug release 
in the non-absorbing distal segment of GIT, leading to poor 
bioavailability [1]. These features are responsible for the design of 
gastro retentive formulations [2, 3]. Dose-dumping is the main 
disadvantage of sustained-release single-unit dosage form due to the 
failure of formulations [4, 5]. Like other multiple unit systems, 
minitablets can be considered a promising approach that releases 
the drug from the subunits (minitablets) after the capsule's 
disintegration [6, 7]. 
The drug having a short biological half-life favors the development 
of a sustained release. In contrast, the drug with an absorption 
window in the upper GI tract favors developing a floating drug 
delivery system, respectively [8, 9]. Metoprolol Succinate, a β-
selective adrenergic blocking agent, 
MATERIALS AND METHODS 
is used to treat patients with 
hypertension or angina pectoris [10]. Metoprolol succinate has a 
short half-life (3-4 h), and absorption window in the upper GI tract 
favors developing a sustained release and floating drug delivery 
system, respectively [11, 12]. It exhibits a high solubility at gastric 
pH 1.2. Hydrophobic polymer can be used in the preparation of 
sustained and floating formulations. Hydrophobicity of certain 
carriers such as Compritol ATO 888, Gelucire 43/0, Gelucire 39/01, 
and precirol ATO 05 is why their release retarding ability [13]. Their 
low melting point makes them suitable for the melt granulation 
method. Higher concentrations of lipophilic carriers promote better 
control of the drug release because of increased lipid matrix density 
and long diffusion path length [14, 15]. Hence in the present 
research work, it is planned to use hydrophobic carriers to 
formulate floating multiple unit minitablets of metoprolol succinate 
to achieve floating with sustain release for 12 h. 
Metoprolol succinate was received as a gift sample from Mepro 
Pharmaceutical Ltd (Gujrat, India). Neusilin US2 was kindly 
provided as ex-gratis by Gangwal Chemicals Pvt Ltd (Mumbai, India). 
Compritol ATO 888, Gelucire 43/01, Gelucire 39/01, and precirol 
ATO 05 were provided as a gift sample from Gattefosse Pvt Ltd 
(Mumbai, India). All other chemicals and solvents used were of 
analytical grade.  
Fusion method was adopted for preparing the solid dispersion of 
metoprolol succinate with a lipophilic carrier such as compritol ATO 
888, gelucire 43/01, gelucire 39/01, and precirol ATO 05. The 
lipophilic carrier was melted on a water bath with continuous 
stirring. To the molten lipid dispersion, metoprolol succinate was 
added and mixed for 10 min. The Neusillin US2 was added to the 
dispersion with continued mixing for 10 min to solidify the molten 
mass. Then the solid dispersion was sieved through mesh no. # 40. 
The resultant dispersion granules were compressed into 3 mm 
circular flat minitablets and were filled into a gelatine capsule of size 
‘0’ [16]. 
Preparation of floating minitablets of metoprolol succinate 
FT-IR analysis of pure drug metoprolol succinate and its dispersion 
granules in 1:1 ratio with compritol ATO888, gelucire 43/01, 
gelucire 39/01, precirol ATO 05, and neusillin US2 were studied on 
IR Affinity-1 (Shimadzu, Japan) using potassium bromide discs. 
Samples were analyzed at a scanning speed of 2 mm/s with a 
resolution of 4 cm-1 over the region 4000–400 cm-1.  
Fourier transform infrared spectroscopy (FT-IR)  
The pure drug metoprolol succinate and its dispersion granules with 
carriers were examined for compatibility study employing DSC 
(Shimazu Ltd., Japan). All the accurately weighed samples were 
placed in sealed aluminum pans before placing the pan on the 
sample holder at a scanning rate of 100C/min from room 
temperature up to 2200C. An empty aluminum pan was used as a 
reference. The DSC curve was plotted over a temperature range to 
predict the thermodynamic compatibility [17]. 
Differential scanning calorimeter (DSC) 
Drug content of dispersion granules and mini tablets were 
determined by weighing an amount equivalent to 10 mg of 
metoprolol succinate in 0.1 N HCl, sonicated for 5 min, filtered, and 
analyzed UV spectrophotometrically at 273 nm. 
Drug content 
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The pure drug metoprolol succinate and dispersion granules of all 
the prepared formulations were characterized for various 
micromeritic properties. The bulk density, tap density, angle of 
repose, Carr’s Index, and Hausner’s ratio of all the formulations were 
determined as per standard procedure [18]. 
Micromeritic properties of dispersion granules 
In vitro buoyancy studies 
The floating lag time was determined by conducting 
Measurement of floating lag time 
In 
vitro buoyancy studies for each of the formulation. The required 
number of floating minitablets was placed in a dissolution jar 
containing 900 ml of 0.1N HCl. Floating lag time may be defined as 
the time required for each of the minitablet to start floating on the 
surface of the dissolution media [19]. 
Floating minitablets were placed in USP dissolution apparatus-II 
containing 900 ml of 0.1N HCl to determine each formulation's 
floating time. Floating time is the total duration of floating when a 
dosage form is placed in a dissolution media [20]. 
Measurement of floating time 
The compressed minitablets were subjected to various quality 
control tests such as weight variation, hardness, thickness, friability, 
and drug content as per the standard procedure [21-23]. 
Evaluation of post-compression parameters 
The 
In vitro dissolution studies 
In vitro dissolution studies of different floating minitablets 
were conducted in a USP dissolution apparatus-II taking 0.1 N HCl 
as dissolution medium. 5 ml sample was withdrawn at regular 
time intervals up to 12 h (0.5, 1, 1.5, 2, 4, 6, 8, 10, and 12 h) and 
was analyzed using UV-spectrophotometer at 273 nm. The drug 
release study's kinetics were analyzed from the dissolution data by 
using zero-order, first-order, Higuchi, and Korsmeyer-Peppas 
model [24, 25]. 
Accelerated stability study of the prepared floating minitablets (F9 
and F14) of metoprolol succinate was conducted for a period of 3 mo 
as prescribed in ICH guidelines. The formulations were examined at 
the time points of 0, 1, 2, and 3 mo for the different parameters. 
Accelerated stability study 
The dose of metoprolol succinate was calculated as 9.2 mg for each 
rabbit of weight approximately 2 kg. The optimized formulation and 
aqueous dispersion of metoprolol succinate were administered in 
dispersion to six male rabbits, each in two groups using Ryle’s tube 
[26]. At different time points (0.5, 2, 4, 8, 12, and 24 h), a blood 
sample of 0.5 ml was withdrawn from the rabbit's marginal ear vein. 
Each blood sample was centrifuged for 10 min at 3000 rpm, and the 
supernatant layer, i.e., serum, was collected using a micropipette. All 
the samples were analyzed using the reverse-phase ultrafast liquid 
chromatographic (UFLC) method. The various pharmacokinetic 
parameters like elimination rate constant (K), half-life (t
In vivo pharmacokinetic study 
1/2), peak 
plasma concentration (Cmax), time to attain the peak plasma 
concentration (Tmax), area under the curve (AUC), area under the 
first moment curve (AUMC) and mean residence time (MRT) were 
calculated. The animal experiment was approved by Institutional 
Animals Ethics Committee [926/PO/Re/5/06/CPCSEA, Approval 
No.97].  
The composition of solid dispersion with different ratios (1:1, 1:2, 
1:3, 1:4, and 1:5) of drug with the lipophilic carrier such as compritol 
ATO 888, gelucire 43/01, gelucire 39/01, and precirol ATO 05 are 
given in (table 1). The ratio of lipophilic carrier to adsorbent 
Neusillin US2 to is maintained at 1:0.5. Each minitablet weighing 20 
mg is filled into a ‘0’ size capsule. The composition of each 
formulation of floating minitablets is illustrated in table 4. 
RESULTS AND DISCUSSION 
 












F1 1 1 - - - 0.5 
F2 1 2 - - - 1 
F3 1 3 - - - 1.5 
F4 1 4 - - - 2 
F5 1 5 - - - 2.5 
F6 1 - 1 - - 0.5 
F7 1 - 2 - - 1 
F8 1 - 3 - - 1.5 
F9 1 - 4 - - 2 
F10 1 - 5 - - 2.5 
F11 1 - - 1 - 0.5 
F12 1 - - 2 - 1 
F13 1 - - 3 - 1.5 
F14 1 - - 4 - 2 
F15 1 - - 5 - 2.5 
F16 1 - - - 1 0.5 
F17 1 - - - 2 1 
F18 1 - - - 3 1.5 
F19 1 - - - 4 2 
F20 1 - - - 5 2.5 
 
Drug-polymer interactions are an important parameter in selecting 
appropriate polymers. FT-IR spectroscopy study was employed to 
ascertain the compatibility between Metoprolol succinate and selected 
polymers. FT-IR study for the pure drug metoprolol succinate showed 
absorption bands at 3181 cm-1 assigned to the NH group, absorption 
bands at 3040 cm-1 assigned to OH group, and absorption bands at 
2740 cm-1 assigned to OCH3
 
 group. The dispersion granules of 
metoprolol succinate with different excipients such as compritol ATO 
888, gelucire 43/01, gelucire 39/01, precirol ATO 05 and neusillin US2 
also showed absorption bands in a similar range; hence metoprolol 
succinate and carriers were compatible with each other [27]. The 
overlaying FT-IR spectrum was shown in fig. 1. 
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Fig. 1: FT-IR study for metoprolol succinate and its dispersion granules 
 
DSC study revealed that the pure drug metoprolol succinate showed 
a sharp endothermic peak at 137.60C with a narrow melting range 
of onset temperature of 1340C and end set temperature 1420C. The 
peaks remained nearly the same in all formulations (fig. 2A and 2B). 
This confirms that no significant overlapping or shifting of the peak 
in the thermogram. However additional peak for each carrier was 
observed [17]. These results of DSC ratifies that the carriers used in 
the present study are compatible with metoprolol succinate. 
  
 
Fig. 2: DSC study for metoprolol succinate and its dispersion granules 
 
Table 2: Micromeritic properties of solid dispersions 
Formulations *Angle of repose ( °) *Carr’s index (C. I.) *Hausner’s ratio (H. R.) *Drug content (%) 
Metoprolol succinate 38±1.2 30±2.3 1.52±1.7 96.7±3.1 
F1 34±1.5 28±2.2 1.32±0.2 99±3.9 
F2 32±2.1 27±1.5 1.27±0.1 96.5±1.2 
F3 35±2.2 28±2.1 1.28±0.2 96±2.3 
F4 33±1.4 26±1.4 1.28±0.2 99±3.2 
F5 32±2.2 29±2.1 1.29±0.3 98±1.4 
F6 31±1.6 27±2.5 1.30±0.3 96±2.6 
F7 32±3.2 26±1.4 1.31±0.2 97±3.1 
F8 33±2.5 25±2.1 1.28±0.3 98±4.7 
F9 35±3.6 26±2.4 1.30±0.3 99±2.3 
F10 27±2.5 18±1.3 1.14±0.2 98±4.1 
F11 24±2.1 19±2.1 1.31±0.4 97±3.3 
F12 25±1.5 18±1.3 1.19±0.4 95±2.6 
F13 22±2.4 18±2.4 1.17±0.3 97±3.7 
F14 24±1.5 17±2.2 1.21±0.2 96±5.4 
F15 23±2.1 19±1.5 1.25±0.2 98±6.2 
F16 24±2.2 18±2.2 1.22±0.7 97±5.1 
F17 22±3.0 17±1.3 1.18±0.4 96±3.2 
F18 25±2.5 16±2.5 1.21±0.3 96±4.1 
F19 28±2.1 20±1.3 1.22±0.2 98±5.2 
F20 26±1.8 21±2.4 1.21±0.3 97±5.2 
*mean±SD, n = 6 
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The drug content for all dispersion granules was more than 90 % 
indicating uniform mixing of drug with carriers (table 2). As the drug 
is dissolved in the molten mass of lipid, it exhibited better drug 
content than other granulation methods. The micromeritic 
parameters for all the formulation as well as the pure drug were 
studied, and the results are depicted in table 2. The pure drug's 
micrometric properties revealed that the flowability and 
compressibility were very poor for processing into the tablet dosage 
form. All the dispersion granules showed that the value of angle of 
repose, C. I and H. R were within the specified limit. This may be due 
to the engulfment of the drug in the molecular structure of the lipid 
matrix. Due to high oil adsorption capacity, the high specific surface 
area of neusillin US2 helps improve compressibility and flowability 
of the prepared dispersion, which can be predicted from their 
micrometric properties. Similar results were also reported about the 
oil adsorption capacity of neusillin US2 for gelucire based dispersion 
granules [16]. 
The In vitro buoyancy study was done, and the value of density, 
floating lag time, and floating time for all the prepared formulations 
are illustrated in table 3. As all floating minitablets' density was much 
lower than the GI fluid density, it was expected that all minitablets 
would float. However, peculiar results were observed in floating 
behavior. Minitablets formulated with gelucire 43/01, and gelucire 
39/01 showed an instantaneous floating behavior, i.e., floating lag time 
of 0 min and floating duration of more than 12 h. In contrast, floating 
minitablets formulated with compritol ATO 888 and precirol ATO 05 
did not exhibit floating despite the low density of minitablets. 
However, Patel, 2015 reported good floating behavior for compritol 
based granules for ranitidine [15]. The In vitro 
  
buoyancy study reveals 
that hydrophobic lipid coat around drug particles' surface is the prime 
reason for floating behavior. It is also predicted that hydrophobicity 
and density alone may not be responsible for achieving desirable 
floating. The nature of the lipid matrix also played a significant role in 
achieving desired floating characteristics. 
Table 3: Determination of density, floating characteristic of mini tablets 
Formulations *Density (g. cm–3 Floating lag time (min) ) Floating duration (h) % Floating 
F1 0.24±0.01 No floating No floating No floating 
F2 0.23±0.03 “ “ “ 
F3 0.27±0.03 “ “ “ 
F4 0.26±0.02 “ “ “ 
F5 0.23±0.04 “ “ “ 
F6 0.19±0.03 0 ˃24 100 
F7 0.22±0.02 0 ˃24 100 
F8 0.22±0.03 0 ˃24 100 
F9 0.25±0.04 0 ˃24 100 
F10 0.20±0.02 0 ˃24 100 
F11 0.21±0.01 0 ˃24 100 
F12 0.23±0.03 0 ˃24 100 
F13 0.22±0.02 0 ˃24 100 
F14 0.21±0.03 0 ˃24 100 
F15 0.24±0.02 0 ˃24 100 
F16 0.27±0.03 No floating No floating No floating 
F17 0.23±0.03 “ “ “ 
F18 0.24±0.02 “ “ “ 
F19 0.22±0.01 “ “ “ 
F20 0.21±0.02 “ “ “ 
*mean±SD, n = 6 
 
The result of the different formulations' quality control test showed 
that the various parameters such as drug content, hardness, 
friability, and disintegration test were within the acceptable 
specification. The In vitro
  
 dissolution study of the formulations was 
carried out, and the plot of cumulative percentage drug release 
against time is illustrated in fig: 3A and 3B. The resultant plot 
suggests that the formulation F9, F10, F14, and F15 were found to 
achieve the desirability of sustaining the drug release for 12 h. 
Similar sustain release of drug was also reported for gelucire 43/01 
based floating beads [14]. 
Table 4: Composition of floating mini tablets 
Ingredients Quantity drug and carriers (mg) in each solid dispersion formulation Number of minitablets 
for 100 mg dose Metprolol succinate Gelucire 43/01 Gelucire 39/01 Neusillin US2 
F6 8 8 - 4 13 
F7 5 10 - 5 20 
F8 3.65 11 - 5.5 33 
F9 2.8 11.5 - 5.7 35 
F10 2.3 11.8 - 5.9 44 
F11 8 - 8 4 13 
F12 5 - 10 5 20 
F13 3.6 - 11 5.5 33 
F14 2.8 - 11.5 5.7 35 
F15 2.3 - 11.8 5.9 44 
 
Table 5 depicts the results of different drug release kinetic 
coefficients for formulations. All formulations exhibited a higher 
correlation for Higuchi equation, and formulations F9, F10, F14, and 
F15 showed release exponent greater than 0.5 less than 1. F9 and 
F14 were found to achieve the desirability of sustaining the drug 
release for 12 h. Hence lipid carrier gelucire 43/01 and gelucire 
39/01are effectively control the drug release in a particular 
composition. Based on the dissolution study F9 and F14 can be 
predicted to satisfy all the floating multiple unit minitablet. 
Formulation F10 and F15 also showed sustained release for 12 h; 
however, keeping in view the minimum amount of carrier, 
formulation F9 and F14 were selected. 
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Table 5: In vitro drug release kinetics 
Formulations Correlation coefficients (r2 Korsmeyer release exponent (n) ) 
Zero-order First-order Higuchi model 
F6 0.7593 0.9606 0.8190 0.2028 
F7 0.8121 0.9732 0.9660 0.4211 
F8 0.7237 0.9790 0.9986 0.5056 
F9 0.9736 0.9902 0.9998 0.5299 
F10 0.9665 0.9998 0.9914 0.5141 
F11 0.6717 0.9873 0.9472 0.2157 
F12 0.7928 0.9801 0.8375 0.2528 
F13 0.8505 0.9948 0.8838 0.5284 
F14 0.9418 0.9949 0.9927 0.5305 
F15 0.9381 0.9956 0.9959 0.5249 
 
Formulation F9 and F14 were examined for 3 mo of stability 
study as prescribed in the method section. The parameters such 
as drug content, floating lag time, floating time, time taken for 
more than 95 percent drug release (T95%) of F9 and F14 at 
various intervals are illustrated in table 6. Analysis of variance 
(p ˂  0.05 levels) indicated no significant change of the 
parameters during the stability study period for F9. However, 
formulation F14 showed a significant change in T95%, which 
may be attributed to softening of gelucire 39/01 at the stability 
study temperature of 400C due to its low melting point. Hence 
floating minitablet formulation F9 was selected for further 
pharmacokinetic study. 
  
Table 6: Accelerated stability study for formulation F9 and F14 

















0 99±2.3 0 ˃12 12±0.2 96±5.4 0 ˃12 12±0.5 
1 98±3.2 0 ˃12 12±0.3 97±3.2 0 ˃12 9±0.2 
2 99±2.5 0 ˃12 12±0.5 96.5±2.5 0 ˃12 9.5±0.4 
3 98±4.1 0 ˃12 12±0.4 96±4.1 0 ˃12 9.3±0.3 
Significance  
At P ˂ 0.05 level 
No sig No sig No sig No sig No sig No sig No sig ** 
*mean±SD, n=6, No sig = No significant difference, **Significant  
 
 
Fig. 3: In vitro drug release profile of gelucire 43/01(3A) and 39/01 (3B) based floating minitablets 
 
Fig. 4 illustrates the mean serum drug concentration of metoprolol 
succinate vs. time graph of the optimized formulation F9 and an 
aqueous suspension of the pure drug after conducting the 
pharmacokinetic study. UFLC method for estimating metoprolol 
succinate using mobile phase acetonitrile: potassium dihydrogen 
phosphate (90:10), C18 column, flow rate 1 ml/min estimates 
retention time of 3.7 min. Table 7 illustrates the calculated values of 
different pharmacokinetic parameters. The Tmax for the pure drug 
was found to be 2 h, whereas Tmax in the case of floating minitablet 
formulation (F9) was 4 h, indicating sustain release of the drug. The 
AUC value of F9 was 167438.19 ng. h/ml. In contrast, it was 
67821.98 ng. h/ml for pure drug, indicating that floating minitablet 
(F9) showed better bioavailability, which is 2.46 times than that of 
the aqueous suspension of pure drug metoprolol succinate. AUMC 
value for F9 was 2.6 times more than the pure drug. Cmax for 
metoprolol succinate was found to be 32125.12 ng/ml, whereas, for 
the selected formulation (F9), it was found to be 40475.58 ng/ml. 
Nearly 1. 2 times increase in Cmax value for F9 indicated better 
absorption of the drug from the formulation. Higher mean residence 
time (MRT) for F9, i.e., 5.96 h in GI tract, indicates increased 
residence time of the dosage form leading to improved 
bioavailability. Hence it may be inferred that it is possible to prepare 
gastro-retentive minitablets using gelucire 43/01 as lipid matrix 
without using a gas generating agent. 
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Table 7: Pharmacokinetics parameters 
Pharmacokinetic parameters Metoprolol succinate Minitablet (F9) 
*Cmax 32125.12±234 (ng/ml) 40475.58±432 
*Tmax 2±0.03 (h) 4±0.03 
*AUC 67821.98±478 (ng. h/ml) 167438.19±769 
*AUMC (ng. h2 192337.67±652 /ml) 519309.97±983 
*MRT (h) 2.8±0.04 5.96±0.02 
*
 
mean±SD, n =6 
 
Fig. 4: Serum drug concentration-time profile of metoprolol succinate and floating minitablet formulation (F9) 
 
In this present research work, formulation and development of 
floating minitablets of metoprolol succinate were carried out with 
desired sustainability and gastric residence time. Solid dispersion 
with different ratios (1:1, 1:2, 1:3, 1:4, and 1:5) of drug with the 
lipophilic carrier such as compritol ATO 888, gelucire 43/01, 
gelucire 39/01, and precirol ATO 05 was formulated using fusion 
technique. The ratio of lipophilic carrier to adsorbent neusillin US2 
is maintained at 1:0.5. Each minitablet weighing 20 mg is filled into a 
‘0’ size capsule. Floating minitablets prepared with compritol ATO 
888 and Precirol ATO 05 did not exhibit floating, whereas gelucire 
43/01 and 39/01 floating minitablets without gas generating agent 
exhibited desirable floating and sustain release characteristics. 
Stability study as per ICH guideline suggests that gelucire 39/01 
based floating minitablets were not stable, but gelucire 43/01 based 
floating minitablets passed the stability test. The pharmacokinetics 
study of the selected formulation (F9) showed 2.46 times increase in 
AUC with increased residence time compared to an aqueous 
suspension of metoprolol succinate. From the above research work, 
it may be concluded that sustain release gastro-retentive minitablets 
can be prepared using gelucire 43/01 without using gas generating 
agents. Hence, gelucire43/01 based minitablets can be considered a 
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